Introduction
Extra skeletal osteosarcomas are uncommon neoplasms representing less than 1% of soft tissue sarcomas. Mammary sarcomas are rarer, accounting for less than 1% of all primary breast malignant tumours. In this group, primary osteosarcomas are one of the least common sarcomas of the breast [1, 2] . Most cases have been reported in the literature as case reports except Silver et al. who reported a retrospective analysis of 50 cases [3] . With less than a hundred cases of primary mammary osteosarcoma reported in the literature [4, 5] .
Extra-skeletal osteosarcoma has been documented in many tissues of the body including the thyroid gland, kidney, bladder, colon, heart, testis, penis, gall bladder and the cerebellum. When it occurs in the breast, it originates either from normal breast tissue de novo, or as metaplastic differentiation of a primary benign or malignant breast lesion. Osteogenic sarcomas of the breast either arising primarily in the breast or as secondary deposits from primary bone sarcomas occur in very rare cases [6] .
Case report
A 24 year-old young lady came to Surgery OPD in PGIMER & Dr. RML Hospital, New Delhi with a 5*4 cm lump in right breast from 3 months (Figs. 4 and 5). TRU cut biopsy showed it was malignant phyllodes tumour. There was no distant metastasis or any axillary lymph nodes palpable. Simple mastectomy was done and the specimen was sent for histopathological examination.
The histology report of showed a malignant phyllodes with chondrosarcomatous differentiation there were malignant spindle cells and osteoclasts like multi-nucleated tumour giant cells. Cartilaginous differentiation with osteoid production were also seen ( Figs. 1-3 ). Resected margins were tumour free. IHC showed vimentin positive in sarcomatous areas and CD 10 positive in spindle cells. She was given 6 cycles of chemotherapy with Doxorubicin, Ifosfamide and mesna by the oncology department.
There was recurrence at the site of surgery after 6 months of surgery, while she was on chemotherapy. Then radical mastectomy with latissimus dorsi musculocutaneous flap was used to cover the anterior chest wall defect. Sections from the mastectomy specimen confirmed the diagnosis of chondroblastic osteosarcoma with spindle cells with marked nuclear pleomorphism, many tumour giant cells, osteoid productions and focal chondroblastic differentiation as in ( Figs. 1-3 ). Axillary nodes were free of tumour cells. 
Follow up
Now the patient again came with recurrence after 5 months, and disseminate subcutaneous nodules over upper abdomen of size 6*6 cm, back, scalp, neck and both forearm. There is a hard lump in her right axilla, with restricted mobility of the right upper limb ( Figs. 4 and 5 ). CECT chest showed left sided mediastinal mass and a necrotic axillary node likely to be malignant. USG abdomen was within normal limits.
Discussion
Malignant phyllodes tumour is a large, unilateral, painless, rapidly progressing lump with boss-elated surface. Median age of 45 years, axillary lymph nodes present in 20% cases. Risk of malignancy in phyllodes tumour is only 5%. FNAC shows dimorphic stromal and epithelial elements. Core needle shows hyper-cellular stromal components and IHC positive for CD10 and NOS (nitric oxide synthase).
Pure sarcomas of the breast are uncommon, accounting for less than 1% of primary breast malignant tumours [7, 8] . More common breast sarcomas include fibrosarcomas, malignant fibrous histiocytoma, angiosarcoma, and liposarcoma [9] . Primary mammary osteosarcoma of the breast represents 12.5% of breast sarcomas [7] .
Tumours with the following criteria are considered 'pure osteosarcoma': absence of bone origin, presence of osteoid or bony matrix, absence of an epithelial differentiation, and absence of a benign tumour.
Mammary osteosarcoma predominates in middle-aged and older women. Most often, they arise as de novo conditions without predisposing factors especially after radiation therapy [3] . All cases reported in literature had unilateral disease [7] .
Clinical features, mammographic and macroscopic findings are not specific [11] . Mammographically, these tumours are usually dense and well-circumscribed with focal or extensive coarse calcifications [7, 12] . Microscopic findings of primary mammary osteosarcoma are similar to skeletal and other extra-skeletal osteosarcomas. Considerable diversity in morphological appearance has been reported with variants like fibroblastic, osteoblastic, osteoclastic, and chondroblastic; a variable amount of osteoid tissue and bone are present in all [7] . Chondrosarcomatous differentiation is unusual as reported in our case [3, 11] .
In localised forms, the treatment is based on surgical excision with clear margins. Lymph node metastases are exceptional so that lymphadenectomy is not indicated. There is controversy regarding the use of chemotherapy. For some authors, it is not recommended especially in localised and well-resected low-grade tumours. Regarding metastasising tumours, treatment is based mainly on chemotherapy using conventional drugs for osteosarcoma (doxorubicin, ifosfamide, cisplatin, methotrexate) [13, 14] .
The prognosis is poor and the five-year survival is 38%. Recurrences are less frequent in patients treated with mastectomy than those treated with local excision. Metastases occur mainly in the lung; there is no axillary node involvement in almost all cases [10] . Cases of death occurring a few months after the diagnosis have been reported [1, 8] .
Conclusion
Chondroblastic osteosarcoma of breast is a very rare malignancy where a definitive diagnosis is established after a histology pathological examination and immunochemistry staining of the specimen. Surgical excision with clear surgical margins remains the cornerstone of treatment. There is limited literature to support the role of local radiotherapy for control of tumour recurrences in patients with primary breast osteosarcoma is still not established.
Take away lesson
Chondroblastic Osteosarcoma of breast Is a highly aggressive tumor with poor prognosis and even after aggressive surgery and adjuvant chemotherapy.
